Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

2017 NCCN Annual Conference

Leo I. Gordon, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses novel immunomodulatory agents and standard treatment options for patients with relapsed or refractory Hodgkin lymphoma.

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Paul M. Cinciripini, PhD, of The University...

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Ruben A. Mesa, MD, of the Mayo Clinic Cance...

Sarcoma

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Suzanne George, MD, of Dana-Farber Cancer I...

Gynecologic Cancers

ASCO Post

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

Christina S. Chu, MD, of Fox Chase Cancer C...

Head and Neck Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

David G. Pfister, MD, of Memorial Sloan Ket...

Mar

Today In Oncology

Leo I. Gordon, MD, on Hodgkin Lymphoma: Management Strategies

Related Videos

Paul M. Cinciripini, PhD, on Smoking Cessation in Patients With Cancer

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines

Suzanne George, MD, on Soft-Tissue Sarcoma: Evolving Treatment

Christina S. Chu, MD, on HPV and Cervical/Vulvar Cancer

David G. Pfister, MD, on HPV and Head and Neck Cancer

Selumetinib for Inoperable Plexiform Neurofibromas in Children With NF1

Continuous Coverage of COVID-19

Managing Cancer Care During the COVID-19 Pandemic

Does Pembrolizumab Show Activity in Some Rare Cancers?

Polypharmacy and Inpatient Hospitalization Rates in Older Patients With Cancer